Ballerup, Denmark

Ninna Willestofte Berg

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Novozymes A/s. Active years: 2010-2013.

USPTO Granted Patents = 2 


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2010-2013

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ninna Willestofte Berg: Innovator in Subtilase Technology

Introduction

Ninna Willestofte Berg is a notable inventor based in Ballerup, Denmark. She has made significant contributions to the field of biotechnology, particularly in the development of subtilase variants. With a total of 2 patents, her work focuses on enhancing the immunogenicity of these enzymes.

Latest Patents

Ninna's latest patents include innovations related to subtilase subtilases with altered immunogenicity. These inventions aim to create subtilases with reduced allergenicity, making them safer for use in various applications. The patents also cover the expression of these subtilase variants and their utilization in products such as detergents and oral care items.

Career Highlights

Ninna Willestofte Berg is currently employed at Novozymes A/S, a leading company in the biotechnology sector. Her work at Novozymes has allowed her to explore and develop innovative solutions that address both industrial and consumer needs.

Collaborations

Throughout her career, Ninna has collaborated with esteemed colleagues, including Erwing Ludo Roggen and Nanna Kristensen Soni. These partnerships have fostered a collaborative environment that enhances the research and development of new biotechnological solutions.

Conclusion

Ninna Willestofte Berg's contributions to subtilase technology exemplify her commitment to innovation in biotechnology. Her patents reflect a dedication to improving product safety and efficacy, making her a valuable asset in her field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…